Scientific work

Doç. Dr. Ahmet Özveren

42 publications. The source of the information is stated next to each publication.

Back to profile

  1. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

    Cancers, 2026

    DOI 10.3390/cancers18121979 PMID 42352512 Open-access full textSource: OpenAlex

  2. Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy

    Cancers, 2026

    DOI 10.3390/cancers18142302 PMID 42512369 Open-access full textSource: ORCID

  3. Impact of oral nutritional support adherence on muscle strength, body composition, and general health status in gastrointestinal cancer patients: ONMUS study

    Nutrition, 2026

    DOI 10.1016/j.nut.2025.113029 PMID 41455457 1 citation (Europe PMC) Source: ORCID

  4. Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70213 PMID 41147655 3 citations (Europe PMC) Source: OpenAlex

  5. Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study

    Discover Oncology, 2025

    DOI 10.1007/s12672-025-03886-1 PMID 41249604 Open-access full textSource: OpenAlex

  6. Impact of Treatment Duration in First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Multicenter Real-World Retrospective Study

    Medicina, 2025

    DOI 10.3390/medicina61071230 PMID 40731859 Open-access full textSource: OpenAlex

  7. Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study

    Cancers, 2024

    DOI 10.3390/cancers17010046 PMID 39796675 9 citations (Europe PMC) Open-access full textSource: ORCID

  8. The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-75293-5 PMID 39384975 1 citation (Europe PMC) Open-access full textSource: ORCID

  9. Alterations in muscle strength among patients with GI cancers receiving oral nutritional support as soon as malnutrition was detected: ONMUS study.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.3_suppl.741 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  10. Is there a role for cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from unusual types of cancer?

    European Journal of Surgical Oncology, 2024

    DOI 10.1016/j.ejso.2023.107866 Source: OpenAlex

  11. Effect of Radiologically Evaluated Sarcopenia on Survival in Advanced Pancreatic Cancer

    The Anatolian Journal of General Medical Research, 2024

    DOI 10.4274/anatoljmed.2023.16432 Open-access full textSource: OpenAlex

  12. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2023

    DOI 10.1007/s00432-023-04766-3 PMID 37067546 7 citations (Europe PMC) Open-access full textSource: OpenAlex

  13. The inflammatory prognostic index as a potential predictor of prognosis in metastatic gastric cancer

    Scientific Reports, 2023

    DOI 10.1038/s41598-023-34778-5 PMID 37173358 10 citations (Europe PMC) Open-access full textSource: ORCID

  14. Real-Life Data of Neoadjuvant Chemotherapy in Breast Cancer: Aegean Region Experience

    European Journal of Therapeutics, 2023

    DOI 10.58600/eurjther.20232902-347.y Open-access full textSource: ORCID

  15. The Close Relationship Between Metabolic Syndrome and Hormone Receptor-Positive Early-Stage Breast Cancer

    Integrative Cancer Therapies, 2023

    DOI 10.1177/15347354231165938 PMID 36987394 Open-access full textSource: ORCID

  16. Second-Line Chemotherapy in Gastric Cancer: a Retrospective Study

    Indian Journal of Surgical Oncology, 2023

    DOI 10.1007/s13193-022-01695-4 PMID 37324318 1 citation (Europe PMC) Open-access full textSource: ORCID

  17. Chemotherapy Choice in Neoadjuvant Dual Her2 Blockade: Is it Really Essential to Add Anthracycline?

    Eurasian Journal of Medical Investigation, 2023

    DOI 10.14744/ejmi.2023.59897 Source: OpenAlex

  18. The Effect of the Modified Glasgow Prognostic Score and Neutrophil/Lymphocyte Ratio on Prognosis in Stage 4 Pancreatic Cancer

    Eurasian Journal of Medical Investigation, 2023

    DOI 10.14744/ejmi.2023.79007 Source: OpenAlex

  19. The effect of the modified Glasgow prognostic score in metastatic gastric cancer

    SVU-International Journal of Medical Sciences, 2023

    DOI 10.21608/svuijm.2023.201018.1554 Open-access full textSource: OpenAlex

  20. Current Topics In Hemato-Oncology

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1576 Open-access full textSource: ORCID

  21. Systemic Immune Inflammation Index as a Key Marker of Survival and Immune-related Adverse Events in Immune Checkpoint Inhibitor Therapy.

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2022

    DOI 10.29271/jcpsp.2022.08.996 PMID 35932122 4 citations (Europe PMC) Open-access full textSource: ORCID

  22. Chemotherapy Choice in Neoadjuvant Dual Her2 Blockade; Is It Really Necessary to Add Anthracycline?

    Research Square, 2022

    DOI 10.21203/rs.3.rs-531944/v2 Open-access full textSource: ORCID

  23. The Inflammatory Prognostic Index; A Potential Predictor In Stage-4 Gastric Cancer

    2022

    DOI 10.21203/rs.3.rs-1264323/v1 Open-access full textSource: ORCID

  24. Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost?

    Journal of Gastrointestinal Cancer, 2022

    DOI 10.1007/s12029-020-00573-y PMID 33400209 1 citation (Europe PMC) Source: ORCID

  25. Palliative Biliary Drainage Has No Effect on Survival in Pancreatic Cancer: Medical Oncology Perspective

    Journal of Gastrointestinal Cancer, 2022

    DOI 10.1007/s12029-021-00754-3 PMID 34767180 1 citation (Europe PMC) Source: ORCID

  26. The Inflammatory Prognostic Index; A Potential Predictor In Stage-4 Gastric Cancer

    ResearchSquare, 2022

    DOI 10.21203/rs.3.rs-1264323 Source: ORCID

  27. Sarkomlar ve Cilt Tümörleri

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1097 Open-access full textSource: OpenAlex

  28. Hepatosellüler Karsinomda Klinik ve Prognostik Özelliklerin Değerlendirilmesi: Tek Merkez Deneyimi

    Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, 2021

    DOI 10.34087/cbusbed.830940 Open-access full textSource: ORCID

  29. Chemotherapy Choice in Neoadjuvant Dual Her2 Blockade; is it Really Necessary to add Anthracycline?

    Research Square, 2021

    DOI 10.21203/rs.3.rs-531944/v1 Open-access full textSource: ORCID

  30. Are Hormonal Agents Better Than Chemo İn Metastati̇c Castrati̇on Resistant Prostate Cancer?

    2021

    DOI 10.21203/rs.3.rs-199255/v1 Open-access full textSource: ORCID

  31. Pancreatic cancer patients who cannot undergo curative surgery live as much as patients over 70 years old.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2021

    DOI 10.21203/rs.3.rs-150867/v1 PMID 34565025 1 citation (Europe PMC) Open-access full textSource: ORCID

  32. Evaluation of sarcopenia, sarcopenic obesity, and phase angle in geriatric gastrointestinal cancer patients: before and after chemotherapy

    Turkish journal of medical sciences, 2019

    DOI 10.3906/sag-1808-114 PMID 30997793 17 citations (Europe PMC) Open-access full textSource: ORCID

  33. Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma

    Indian Journal of Cancer, 2019

    DOI 10.4103/ijc.ijc_355_18 PMID 30950435 1 citation (Europe PMC) Source: ORCID

  34. The effect of chemotherapy on nutritional status and weakness in geriatric gastrointestinal system cancer patients

    Nutrition, 2018

    DOI 10.1016/j.nut.2017.09.013 PMID 29429533 19 citations (Europe PMC) Source: ORCID

  35. SUN-P078: Determination of Malnutrition and Sarcopenia in Geriatric Patients with Gastrointestinal Malignancy

    Clinical Nutrition, 2016

    DOI 10.1016/s0261-5614(16)30421-6 Source: OpenAlex

  36. Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines

    Cancer Chemotherapy and Pharmacology, 2015

    DOI 10.1007/s00280-015-2756-1 PMID 25925002 12 citations (Europe PMC) Source: ORCID

  37. Prognostic effect of tumor location in stage II and III colon cancer

    Journal of Clinical Oncology, 2015

    DOI 10.1200/jco.2015.33.15_suppl.e14652 Source: ORCID

  38. Prognostic role of neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with docetaxel

    Journal of Clinical Oncology, 2015

    DOI 10.1200/jco.2015.33.15_suppl.e16050 2 citations (OpenAlex) Source: ORCID

  39. SUN-PP124: Correlation between Mini Nutritional Assessment and Hand Grip Strength in Geriatric Patients with Gastrointestinal Cancer

    Clinical Nutrition, 2015

    DOI 10.1016/s0261-5614(15)30275-2 Source: OpenAlex

  40. A Case of Crescentic Glomerulonephritis That Developed After Marijuana Use

    Turkiye Klinikleri Journal of Nephrology, 2014

    Source: OpenAlex

  41. A puzzling case of phospho-soda-induced hypocalcemia in a patient with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism

    Internal Medicine, 2012

    DOI 10.2169/internalmedicine.51.7475 PMID 23154721 1 citation (Europe PMC) Open-access full textSource: ORCID

  42. Mortality In Geriatric Patients With Upper Gastrointestinal Bleeding

    The Anatolian Journal of General Medical Research, 2012

    DOI 10.5222/terh.2012.73466 2 citations (OpenAlex) Open-access full textSource: OpenAlex